RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established global rare disease commercial infrastructure Moderna will continue to lead development for mRNA-3927, and if approved, Recordati will lead global commercialization efforts Milan, 29 January 2026 – Recordati today announced that it has entered into a...
RECORDATI ANNUNCIA UNA COLLABORAZIONE STRATEGICA CON MODERNA PER SVILUPPARE E COMMERCIALIZZARE A LIVELLO GLOBALE mRNA-3927 PER IL TRATTAMENTO DELL’ACIDEMIA PROPIONICA mRNA-3927 si inserisce strategicamente nel portafoglio delle malattie rare metaboliche di Recordati La collaborazione unisce l’expertise di Moderna nella tecnologia mRNA per i disturbi metabolicirari con la solida infrastruttura commerciale globale di Recordati nelle malattie rare Moderna continuerà a guidare lo sviluppo di mRNA-3927 e, in caso di approvazione, Recordati guiderà la commercializzazione a livello globale Mila...
A director at Recordati bought 21,050 shares at 47.495EUR and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
In today's Morning Views publication we comment on developments of the following high yield issuers: Vallourec, Rekeep, Advanz Pharma, Kelvion (formerly Galapagos Holding), Recordati, Lecta, Clarios, Ardagh, Crown Holdings, TUI, David Lloyd Leisure, Centrient, Azelis
Carrefour has reportedly received three offers for its Romanian business, including one from Auchan.|Permira is reportedly negotiating the sale of Golden Goose for more than € 2.5bn to Hongshan|Edenred has significantly revised downwards its EBITDA forecast for 2026 if regulatory changes in Brazil are confirmed.|
Carrefour aurait reçu trois offres pour son activité en Roumanie dont une d’Auchan.|Permira négocierait la cession de Golden Goose au fond Hongshang Capital pour plus de 2,5 mds EUR|Edenred revoit en forte baisse sa prévision d’EBITDA pour 2026 si les changements règlementaires au Brésil venaient à être confirmés.|
In today's Morning Views publication we comment on developments of the following high yield issuers: Sunrise, Bite, TK Elevator, Italmatch Chemicals, Nimlas, Lowell, Intralot, Recordati, Klockner Pentaplast, Standard Profil, Advanz Pharma, Softbank Group, Ineos
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION NEWS RELEASE RECORDATI FIRST NINE MONTHS 2025 RESULTS:REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION Consolidated net revenue of € 1,956.2 million in the first nine months of 2025, +12.2% or +8.1% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 743.9 million, +11.8%, margin on revenue of 38.0%Adjusted ne...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.